Equities researchers at StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Get Free Report) in a research report issued on Monday. The brokerage set a “hold” rating on the stock.
Brooklyn ImmunoTherapeutics Trading Down 5.6 %
Shares of BTX opened at $1.78 on Monday. Brooklyn ImmunoTherapeutics has a 12 month low of $0.17 and a 12 month high of $10.10. The firm has a fifty day simple moving average of $1.98 and a 200 day simple moving average of $1.99. The stock has a market capitalization of $104.71 million, a price-to-earnings ratio of -0.78 and a beta of 4.61.
About Brooklyn ImmunoTherapeutics
See Also
- Five stocks we like better than Brooklyn ImmunoTherapeutics
- 3 Grocery Stocks That Are Proving They Are Still Essential
- RXO Shares Surge Following New Acquisition Deal
- How to Invest in Biotech Stocks
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- What Investors Need to Know to Beat the Market
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.